Table 3c. Therapeutic Management of Hospitalized Children With COVID-19
Last Updated: August 8, 2022
|Disease Severity||Panel's Recommendations|
|Hospitalized for COVID-19||For children aged ≥12 years admitted for COVID-19, use prophylactic anticoagulation unless contraindicated (BIII).|
|Does Not Require Supplemental Oxygen||For children admitted for COVID-19 who are at the highest risk of progression to severe COVID-19,a consider using remdesivirb for children aged 12–17 years (CIII). There is insufficient evidence for using remdesivir in children aged 28 days to <12 years.|
|For children admitted for reasons other than COVID-19 who have mild to moderate COVID-19 and are at the highest risk of progression,a refer to Therapeutic Management of Nonhospitalized Children With COVID-19.|
|Requires Conventional Oxygenc||Use 1 of the following options: |
|Requires Oxygen Through High-Flow Device or NIVd||Use 1 of the following options: |
|For children who do not have rapid (e.g., within 24 hours) improvement in oxygenation after initiation of dexamethasone, baricitinibe or tocilizumab can be considered for children aged 12–17 years (BIII) and for children aged 2–11 years (CIII).|
|Requires MV or ECMOf||Dexamethasonef (AIII)|
|For children who do not have rapid (e.g., within 24 hours) improvement in oxygenation after initiation of dexamethasone, baricitinibe or tocilizumab may be considered for children aged 12–17 years (BIII) and for children aged 2–11 years (CIII).|
|Rating of Recommendations: A = Strong; B = Moderate; C = Weak|
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion
a For example, for children who are severely immunocompromised regardless of COVID-19 vaccination status and those who are unvaccinated and have additional risk factors for progression (see Therapeutic Management of Nonhospitalized Children With COVID-19).
b The clinical benefit of remdesivir is greatest if it is initiated within 10 days of symptom onset. Remdesivir should be given for 5 days or until hospital discharge, whichever comes first.
c Conventional oxygen refers to oxygen supplementation that is not high-flow oxygen, NIV, MV, or ECMO.
d Patients who are receiving NIV or MV at baseline and require a substantial increase in baseline support should be treated per the recommendations for patients requiring new NIV or MV.
e Tofacitinib is an alternative if baricitinib is not available (BIII).
f For children who started receiving remdesivir before admission to the ICU, the remdesivir should be continued to complete the treatment course.
Key: ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; MV = mechanical ventilation; NIV = noninvasive ventilation